News

Video

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

Author(s):

Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ,Manish Shah, MD

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Related Videos
Related Content